Soleno Therapeutics to Participate in the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
Soleno Therapeutics (NASDAQ: SLNO) will have its CEO, Anish Bhatnagar, present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 20, 2021, at 1:15 PM ET. A live audio webcast will be accessible via the company's website. Soleno is dedicated to developing therapeutics for rare diseases, with its lead candidate, DCCR extended-release tablets, currently in Phase 3 trials for Prader-Willi Syndrome.
- None.
- None.
REDWOOD CITY, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on Monday, September 20, 2021 at 1:15 PM Eastern Time.
A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
FAQ
When is Soleno Therapeutics' corporate overview presentation at the Oppenheimer Summit?
Who will present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit?
What is the lead candidate of Soleno Therapeutics and what condition does it target?
Where can I find the audio webcast of Soleno Therapeutics' presentation?
What is the stock symbol of Soleno Therapeutics?
